<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313491851</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313491851</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The CD11b-integrin (<italic>ITGAM</italic>) and systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Fagerholm</surname><given-names>SC</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313491851">1</xref>
<xref ref-type="aff" rid="aff2-0961203313491851">2</xref>
<xref ref-type="corresp" rid="corresp1-0961203313491851"/>
</contrib>
<contrib contrib-type="author">
<name><surname>MacPherson</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313491851">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>James</surname><given-names>MJ</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313491851">1</xref>
<xref ref-type="aff" rid="aff3-0961203313491851">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sevier-Guy</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313491851">1</xref>
<xref ref-type="aff" rid="aff4-0961203313491851">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lau</surname><given-names>CS</given-names></name>
<xref ref-type="aff" rid="aff5-0961203313491851">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203313491851"><label>1</label>Medical Research Institute, Ninewells Hospital and Medical School</aff>
<aff id="aff2-0961203313491851"><label>2</label>Institute of Biotechnology, University of Helsinki, Finland</aff>
<aff id="aff3-0961203313491851"><label>3</label>College of Life Sciences, University of Dundee, UK</aff>
<aff id="aff4-0961203313491851"><label>4</label>National Health Service Tayside, UK</aff>
<aff id="aff5-0961203313491851"><label>5</label>Division of Rheumatology and Clinical Immunology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong</aff>
<author-notes>
<corresp id="corresp1-0961203313491851">Susanna C Fagerholm, Medical Research Institute, Jacqui Wood Cancer Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. Email: <email>s.c.fagerholm@dundee.ac.uk</email> New address: Institute of Biotechnology, P.O. Box 56, 00014 University of Helsinki, Finland. Email: susanna.fagerholm@helsinki.fi</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>7</issue>
<fpage>657</fpage>
<lpage>663</lpage>
<history>
<date date-type="received"><day>27</day><month>2</month><year>2013</year></date>
<date date-type="accepted"><day>30</day><month>4</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Variations at the <italic>ITGAM</italic> gene, which encodes for the CD11b chain of the Mac-1 (alphaMbeta2; CD11b/CD18; complement receptor-3) integrin, is one of the strongest genetic risk factors for systemic lupus erythematosus (SLE). More specifically, a genetic variant (rs1143679) which results in an arginine to histidine substitution at position 77 in the extracellular portion of the integrin is associated with disease. It has recently been shown that this amino acid substitution results in a dysfunctional integrin, which is deficient in mediating cell adhesion to integrin ligands, phagocytosis and in addition cannot restrict inflammatory cytokine production in macrophages. In this review, we discuss immunological functions of the Mac-1 integrin and how defects in the genetic variant of Mac-1 may relate to SLE development.</p>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd><italic>ITGAM</italic></kwd>
<kwd>integrin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313491851" sec-type="intro"><title>Introduction</title>
<p>In recent years several genome-wide association studies have been performed on systemic lupus erythematosus (SLE) patients. Although much remains to be elucidated about the heritability of lupus, there is now an increased understanding of genes contributing to SLE disease risk. However, there is still limited knowledge of the molecular and immunological mechanisms by which these genes and genetic variants contribute to SLE pathogenesis and disease risk. Understanding why these gene polymorphisms predispose to SLE will aid our understanding of the immune pathogenesis of disease and may identify novel therapeutic targets.</p>
</sec>
<sec id="sec2-0961203313491851"><title>The genetic association of <italic>ITGAM</italic>/CD11b and SLE</title>
<p>SLE is a clinically heterogeneous autoimmune inflammatory disease with a strong genetic component (sibling risk ratio 20–29).<sup><xref ref-type="bibr" rid="bibr1-0961203313491851">1</xref></sup> Recent genome-wide association studies have identified the <italic>ITGAM</italic> gene on 16p11.2, which encodes the CD11b chain of CD11b/CD18 integrin (also called Mac-1, alphaMbeta2, CR3) as a major contributory gene.<sup><xref ref-type="bibr" rid="bibr2-0961203313491851">2</xref><xref ref-type="bibr" rid="bibr3-0961203313491851"/><xref ref-type="bibr" rid="bibr4-0961203313491851"/>–<xref ref-type="bibr" rid="bibr5-0961203313491851">5</xref></sup> In several recent genome-wide association studies, a robust association between the <italic>ITGAM-ITGAX</italic> region and SLE susceptibility has been reported.<sup><xref ref-type="bibr" rid="bibr2-0961203313491851">2</xref>,<xref ref-type="bibr" rid="bibr4-0961203313491851">4</xref></sup></p>
<p>More specifically, a non-synonymous variant, rs1143679, is very robustly associated with SLE.<sup><xref ref-type="bibr" rid="bibr3-0961203313491851">3</xref></sup> This has been confirmed in multiple independent patient cohorts of different ethnicity and in a recent meta-analysis comprising 12,000 patients and 17,000 controls.<sup><xref ref-type="bibr" rid="bibr5-0961203313491851">5</xref><xref ref-type="bibr" rid="bibr6-0961203313491851"/>–<xref ref-type="bibr" rid="bibr7-0961203313491851">7</xref></sup> Interestingly, in certain Asian populations, only the non-disease-associated variant of the gene is present and therefore cannot be contributing to disease risk.<sup><xref ref-type="bibr" rid="bibr6-0961203313491851">6</xref></sup> Importantly, this <italic>ITGAM</italic> coding variant influences the risk of renal disease, discoid rash and immunological manifestations in SLE patients.<sup><xref ref-type="bibr" rid="bibr7-0961203313491851">7</xref>,<xref ref-type="bibr" rid="bibr8-0961203313491851">8</xref></sup> Also, other genetic variants of <italic>ITGAM</italic>, as well as genes encoding integrin ligands intercellular adhesion molecule (ICAM)-1-ICAM-4-ICAM-5, and putative integrin ligands, such as MAMDC1, have been reported to be associated with SLE; for the most part, these remain to be confirmed in further analyses.<sup><xref ref-type="bibr" rid="bibr5-0961203313491851">5</xref>,<xref ref-type="bibr" rid="bibr9-0961203313491851">9</xref><xref ref-type="bibr" rid="bibr10-0961203313491851"/>–<xref ref-type="bibr" rid="bibr11-0961203313491851">11</xref></sup> <italic>ITGAM</italic>, however, is not associated with other autoimmune diseases, such as rheumatoid arthritis (the only exception being systemic sclerosis), arguing for a specific role of this gene in SLE pathogenesis rather than a general role in immune dysregulation.<sup><xref ref-type="bibr" rid="bibr12-0961203313491851">12</xref><xref ref-type="bibr" rid="bibr13-0961203313491851"/>–<xref ref-type="bibr" rid="bibr14-0961203313491851">14</xref></sup></p>
</sec>
<sec id="sec3-0961203313491851"><title>Immunological functions of the CD11b/Mac-1 integrin</title>
<p><italic>ITGAM</italic> encodes for the CD11b-integrin (alphaM) polypeptide, which pairs with the CD18-integrin polypeptide to form a functional Mac-1-integrin. Other members of this leucocyte-specific CD18- or beta2-integrin family include LFA-1 (alphaLbeta2; CD11a/CD18), alphaXbeta2 (CD11c/CD18; CR4) and alphaDbeta2 (CD11d/CD18). These heterodimeric receptors all share the common integrin beta2 or CD18 chain, but have different alpha-chains, different expression in leucocytes, different ligands and mediate different functions in the immune system<sup><xref ref-type="bibr" rid="bibr15-0961203313491851">15</xref></sup> (<xref ref-type="table" rid="table1-0961203313491851">Table 1</xref>). For example, LFA-1 is expressed in all leucocytes and is crucial for recruitment of leucocytes into tissue by binding to ICAM-1 expressed on the surface of endothelial cells and mediating firm adhesion under flow conditions. Indeed, patients with Leucocyte Adhesion Deficiency (LAD)-I, in which expression of these integrins is low or absent, suffer from recurrent bacterial infections because of a deficiency of leucocyte (neutrophil) recruitment into tissue.<sup><xref ref-type="bibr" rid="bibr16-0961203313491851">16</xref></sup>
<table-wrap id="table1-0961203313491851" position="float"><label>Table 1</label><caption><p>beta2-integrins and their roles in the immune system and SLE</p></caption>
<graphic alternate-form-of="table1-0961203313491851" xlink:href="10.1177_0961203313491851-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Integrin</th>
<th>Synonyms</th>
<th>Functions</th>
<th>Potential contribution to SLE pathology</th>
</tr></thead>
<tbody align="left">
<tr>
<td>LFA-1</td>
<td>CD11a/CD18, αLβ2</td>
<td>Binds to ICAMs. Mediates leukocyte homing and recruitment into inflammatory sites. Stabilizes T cell-APC interaction (the immune synapse).</td>
<td>Loss of LFA-1 function protects against lupus development in mouse models whereas overexpression leads to a lupus-like syndrome.<sup><xref ref-type="bibr" rid="bibr26-0961203313491851">26</xref>,<xref ref-type="bibr" rid="bibr27-0961203313491851">27</xref></sup></td>
</tr>
<tr>
<td>Mac-1</td>
<td>CD11b/CD18, αMβ2, CR3</td>
<td>Binds to complement component iC3b, ICAM-1 and many other ligands. Mediates phagocytosis of iC3b-coated particles (apoptotic cells, pathogens), and immune complex clearance. Involved in leucocyte trafficking to sites of inflammation. Inhibits T-cell activation, restricts TLR signalling and Th17 cell differentiation.<sup><xref ref-type="bibr" rid="bibr19-0961203313491851">19</xref><xref ref-type="bibr" rid="bibr20-0961203313491851"/><xref ref-type="bibr" rid="bibr21-0961203313491851"/><xref ref-type="bibr" rid="bibr22-0961203313491851"/><xref ref-type="bibr" rid="bibr23-0961203313491851"/><xref ref-type="bibr" rid="bibr24-0961203313491851"/>–<xref ref-type="bibr" rid="bibr25-0961203313491851">25</xref></sup></td>
<td><italic>ITGAM</italic>-locus and rs1143679 variant associated with SLE.<sup><xref ref-type="bibr" rid="bibr2-0961203313491851">2</xref><xref ref-type="bibr" rid="bibr3-0961203313491851"/><xref ref-type="bibr" rid="bibr4-0961203313491851"/>–<xref ref-type="bibr" rid="bibr5-0961203313491851">5</xref></sup> Impaired phagocytosis may lead to defective removal of apoptotic cells and/or immune complexes. Reduced inhibition of T-cell activation, TLR signalling, or Th17 differentiation may result in increased systemic inflammation.<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref>,<xref ref-type="bibr" rid="bibr29-0961203313491851">29</xref></sup></td>
</tr>
<tr>
<td>αXβ2</td>
<td>CD11c/CD18, CR4</td>
<td>Binds iC3b, fibrinogen, ICAMs. Similar to Mac-1. Mediates phagocytosis. Binds fibrinogen and ICAM molecules and may play a role in leucocyte adhesion and migration. Marker for dendritic cells.</td>
<td>A genome-wide association study identified the <italic>ITGAM-ITGAX</italic> locus as associated with SLE.<sup><xref ref-type="bibr" rid="bibr2-0961203313491851">2</xref></sup></td>
</tr>
<tr>
<td>αDβ2</td>
<td>CD11d/CD18</td>
<td>The most recently discovered beta2-integrin. Relatively poorly understood receptor.</td>
<td>To date, there is no known association with <italic>ITGAD</italic> and SLE.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313491851"><p>SLE: systemic lupus erythematosus; ICAMs: intercellular adhesion molecules; APC: antigen-presenting cell; TLR: toll-like receptor.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Beta2-integrins are complex cell surface receptors, mediating both so-called “inside-out” and “outside-in” signalling.<sup><xref ref-type="bibr" rid="bibr15-0961203313491851">15</xref>,<xref ref-type="bibr" rid="bibr17-0961203313491851">17</xref></sup> “Inside-out” refers to the activation of integrins through intracellular signalling pathways initiated by other surface receptors such as the T cell receptor, chemokine receptors and Toll-like receptors (TLRs) (among others). Inside-out signalling results in conformational changes in the integrin, resulting in increased affinity for soluble ligands, ligands on the surface of other cells, or in the extracellular matrix. After ligand binding, integrins can mediate outside-in signalling, leading to changes in the actin cytoskeleton, cell spreading, phagocytosis, cell migration, and changes in signalling and gene expression. Both inside-out and outside-in signalling are mediated by the binding of intracellular factors, such as talin, kindlin-3, filamin and 14-3-3 proteins, to the short intracellular domains (tails) of integrins.<sup><xref ref-type="bibr" rid="bibr17-0961203313491851">17</xref></sup></p>
<p>Mac-1 is predominantly expressed on myeloid cells such as macrophages, neutrophils and dendritic cells (DCs). It binds a wide variety of ligands, including those of the ICAM family, the complement protein iC3b and fibrinogen. Mac-1 mediates phagocytosis of iC3b-coated particles, such as apoptotic cells.<sup><xref ref-type="bibr" rid="bibr18-0961203313491851">18</xref></sup> It also contributes to leucocyte trafficking to sites of inflammation, through binding ICAM-ligands on blood vessel endothelium, thereby assisting in crawling of neutrophils on endothelium before extravasation takes place.<sup><xref ref-type="bibr" rid="bibr19-0961203313491851">19</xref>,<xref ref-type="bibr" rid="bibr20-0961203313491851">20</xref></sup> Mac-1 has also been reported to have numerous other ligands and therefore is considered to be highly promiscuous.<sup><xref ref-type="bibr" rid="bibr15-0961203313491851">15</xref></sup></p>
<p>Interestingly, Mac-1 has recently been shown to inhibit several immunological processes. Mac-1 restricts DC maturation and function<sup><xref ref-type="bibr" rid="bibr21-0961203313491851">21</xref></sup> and DC-induced T cell activation.<sup><xref ref-type="bibr" rid="bibr22-0961203313491851">22</xref></sup> Mac-1 also plays a role in oral tolerance by restricting Th17 differentiation.<sup><xref ref-type="bibr" rid="bibr23-0961203313491851">23</xref></sup> In macrophages, Mac-1 restricts TLR signalling through Src/Syk signalling, which results in degradation of TLR pathway downstream signalling components myeloid differentiation primary response 88 (MyD88) and TRIF,<sup><xref ref-type="bibr" rid="bibr24-0961203313491851">24</xref></sup> and Mac-1 has also been implicated in dampening macrophage responses through induction of signalling inhibitors such as suppressor of cytokine signalling 3 (SOCS3) and protein A20, as well as interleukin (IL)−10.<sup><xref ref-type="bibr" rid="bibr25-0961203313491851">25</xref></sup></p>
<p>Interestingly, loss of LFA-1 protects MRL/MpJ-Fas<sup>lpr</sup> mice from developing lupus,<sup><xref ref-type="bibr" rid="bibr26-0961203313491851">26</xref></sup> whilst LFA-1 overexpressing mice develop a lupus-like disease.<sup><xref ref-type="bibr" rid="bibr27-0961203313491851">27</xref></sup> In contrast, Mac-1 –/– mice display exacerbated disease, demonstrating that these integrins play different roles in immune regulation in vivo and in lupus development.<sup><xref ref-type="bibr" rid="bibr26-0961203313491851">26</xref></sup></p>
</sec>
<sec id="sec4-0961203313491851"><title>Effects of the arginine to histidine substitution on Mac-1 immunological functions</title>
<p>The <italic>ITGAM</italic> rs1143679 coding variant results in an arginine to histidine amino acid change at position 77 in the extracellular domain of the CD11b-integrin (R77H). This amino acid is in the beta-propeller domain of the integrin, in close proximity to the main ligand-binding I-domain. So, how does the mutation affect integrin function? We have recently shown that the R77H mutation in the integrin extracellular domain does not influence the surface expression of the integrin when transfected into leucocyte cell lines.<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref></sup> It also does not affect heterodimerization with the CD18/beta2 subunit, or the ability of the integrin to undergo conformational changes associated with activation of the integrin, and only marginally affects binding of soluble ligands to the integrin. These results suggest that inside-out signalling through the integrin is relatively normal. However, the R77H substitution dramatically influences the ability of the integrin to mediate cell adhesion to ligands such as ICAM-1 and -2 as well as iC3b, both under static conditions and under conditions of shear flow (mimicking blood flow).<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref></sup> Importantly, these results were later confirmed in a study using human cells expressing the R77H variant of the integrin.<sup><xref ref-type="bibr" rid="bibr29-0961203313491851">29</xref></sup></p>
<p>Mac-1 is an important receptor for iC3b and therefore mediates phagocytosis of opsonized particles such as apoptotic cells or possibly immune complexes.<sup><xref ref-type="bibr" rid="bibr18-0961203313491851">18</xref></sup> Importantly, the R77H substitution severely reduces phagocytosis of complement opsonized particles.<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref>,<xref ref-type="bibr" rid="bibr29-0961203313491851">29</xref></sup> Interestingly, this defect in phagocytosis can be seen already in cells heterozygous for the variant allele.<sup><xref ref-type="bibr" rid="bibr30-0961203313491851">30</xref></sup></p>
<p>Mac-1 is also an important negative regulator of immune cell signalling.<sup><xref ref-type="bibr" rid="bibr24-0961203313491851">24</xref></sup> We and others have shown that the R77H-substituted integrin fails to downregulate IL-6 expression in macrophages, demonstrating that the integrin, which fails to mediate cell adhesion, is also deficient in regulating proinflammatory cytokine production.<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref>,<xref ref-type="bibr" rid="bibr29-0961203313491851">29</xref></sup></p>
</sec>
<sec id="sec5-0961203313491851"><title>What is the mechanism(s) by which the altered Mac-1 receptor contributes to SLE development?</title>
<p>It is plausible that the decreased binding of R77H Mac-1 to iC3b and the reduction in phagocytosis contributes to disease, perhaps through reduced clearance of apoptotic cells, thereby contributing to reduced “waste disposal” which has been postulated as a disease mechanism in lupus<sup><xref ref-type="bibr" rid="bibr31-0961203313491851">31</xref>,<xref ref-type="bibr" rid="bibr32-0961203313491851">32</xref></sup> (<xref ref-type="fig" rid="fig1-0961203313491851">Figure 1</xref>). Disturbed apoptosis or defective clearance of apoptotic cells may result in the activation of DCs, inflammatory cytokine production, and uptake and presentation of nuclear antigens to T cells.<sup><xref ref-type="bibr" rid="bibr33-0961203313491851">33</xref></sup> On the other hand, binding of apoptotic cells to phagocytic receptors is an anti-inflammatory process which dampens cytokine productions in cells, and this process may be deficient for R77H-Mac-1-expressing cells, further exacerbating disease. However, the exact role and contribution of Mac-1 in clearance of apoptotic cells requires further investigation.<sup><xref ref-type="bibr" rid="bibr18-0961203313491851">18</xref>,<xref ref-type="bibr" rid="bibr34-0961203313491851">34</xref></sup> In addition, or alternatively, Mac-1 may be involved in clearance of immune complexes, which of course are main contributors of tissue damage in lupus.
<fig id="fig1-0961203313491851" position="float"><label>Figure 1</label><caption><p>Possible effects of the R77H substitution in Mac-1 on SLE development.</p>
<p>The R77H substitution in Mac-1 is associated with reduced adhesion to iC3b and reduced phagocytosis, as well as increased inflammatory cytokine production. It is possible that the reduced phagocytic uptake of apoptotic cells leads to secondary necrosis, resulting in release of nuclear proteins into the surrounding tissue. These can be taken up by dendritic cells and nuclear antigens presented to Th1/Th17 cells, leading to T cell activation and subsequent activation of B cells which then produce antibodies to the nuclear antigens, a hallmark for SLE. Immune complexes are deposited in small vessels leading to vasculitis and also to further recruitment of immune cells into tissue, fuelling tissue damage and inflammation. It is also possible that reduced phagocytosis results in impaired uptake of immune complexes. Mac-1 has also been described to inhibit T cell and dendritic cell activation and Th17 development, and defects in these processes may also influence SLE development. For further details, see text.</p>
<p>SLE: systemic lupus erythematosus.</p></caption><graphic xlink:href="10.1177_0961203313491851-fig1.tif"/>
</fig></p>
<p>The R77H substitution affects cell adhesion to many different integrin ligands,<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref>,<xref ref-type="bibr" rid="bibr29-0961203313491851">29</xref></sup> but does not affect expression of integrin “activation epitopes”, which are indicative of conformational changes upon inside-out signalling to integrins.<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref></sup> This suggests that outside-in signalling, normally leading to adhesion strengthening and cell adhesion to a coated ligand, is affected by the R77H substitution in the integrin. The R77H-associated defect in phagocytosis also indicates that outside-in signalling may be affected by this amino acid substitution.<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref></sup> A defect in outside-in signalling may be associated with a failure to negatively regulate immune cells, as also indicated by increased proinflammatory cytokine production in R77H-expressing cells.<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref></sup> Beta2-integrins signal through Src/Syk kinases, Pyk2, Rho and Rac/Cdc42 pathways; it remains to be investigated if these pathways are disrupted in R77H-Mac-1-expressing myeloid cells, perhaps leading to an inability of the R77H mutated integrin to mediate phagocytosis or to suppress myeloid cell activation. However, the polymorphism is not associated with other autoimmune disorders, such as rheumatoid arthritis, perhaps arguing for a specific effect of the R77H substitution on Mac-1-mediated phagocytosis.</p>
<p>Mac-1 is also associated with suppressing Th17 cell development,<sup><xref ref-type="bibr" rid="bibr23-0961203313491851">23</xref></sup> another factor which may be important in SLE development,<sup><xref ref-type="bibr" rid="bibr35-0961203313491851">35</xref></sup> but as the H77-variant of the receptor is not associated with a generalized autoimmunity phenotype, this seems like an unlikely explanation.</p>
<p>Another possibility is that the decreased binding to ICAM-1/2 plays a contributing role, either through influencing leucocyte trafficking or signalling, but although ICAM genetic variants have been implicated in lupus, the effects seem to be independent of the Mac-1 variants,<sup><xref ref-type="bibr" rid="bibr11-0961203313491851">11</xref></sup> possibly indicating that these molecules do not affect lupus development through a common pathway.</p>
</sec>
<sec id="sec6-0961203313491851"><title>Outstanding questions</title>
<p>Mac-1 is expressed on multiple cell types such as monocytes, macrophages, DCs, neutrophils and even B cell subsets. Elucidating immunological mechanisms through which the R77H mutated receptor elicits effects on SLE development therefore clearly requires further study.</p>
<p>In the future, it will be interesting to investigate these genetic variants in conjunction with other molecules of the opsonization pathway, such as Fc-receptors, which are involved in clearance of immune complexes and collaborate with Mac-1 for many functions<sup><xref ref-type="bibr" rid="bibr36-0961203313491851">36</xref><xref ref-type="bibr" rid="bibr37-0961203313491851"/>–<xref ref-type="bibr" rid="bibr38-0961203313491851">38</xref></sup> and which are also disease susceptibility genes for SLE.<sup><xref ref-type="bibr" rid="bibr39-0961203313491851">39</xref></sup> Indeed, Mac-1 and Fc receptors have been shown to functionally interact in lupus models in vivo.<sup><xref ref-type="bibr" rid="bibr40-0961203313491851">40</xref></sup> Also putative Mac-1 ligands associated with SLE, such as MAMDC1, will be interesting to examine in the future.<sup><xref ref-type="bibr" rid="bibr9-0961203313491851">9</xref></sup></p>
<p>Therapeutic targeting of the R77H variant of Mac-1 may be an option in the future. Interestingly, compounds which specifically target Mac-1 and activate cell adhesion have been described<sup><xref ref-type="bibr" rid="bibr41-0961203313491851">41</xref>,<xref ref-type="bibr" rid="bibr42-0961203313491851">42</xref></sup> and have been used in vivo in various inflammatory models.<sup><xref ref-type="bibr" rid="bibr42-0961203313491851">42</xref></sup> In this regard, it is interesting that it might be possible to rescue R77H-Mac-1-mediated cell adhesion with such small molecules, although the effect on R77H-Mac-1-mediated cell adhesion to iC3b is quite modest with such compounds (<xref ref-type="fig" rid="fig2-0961203313491851">Figure 2</xref>). In addition, such compounds have been used to attenuate the effect of the R77H-Mac-1 on TLR signalling.<sup><xref ref-type="bibr" rid="bibr43-0961203313491851">43</xref></sup> Targeting Mac-1-mediated signalling may be another therapeutic option.
<fig id="fig2-0961203313491851" position="float"><label>Figure 2</label><caption><p>IMB-10 partially rescues the adhesion defect caused by the SLE-associated R77H-substitution in Mac-1.</p>
<p>Cell adhesion of wt-Mac-1 and R77H-Mac-1 transfected Jbeta2.7 cells<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref></sup> to coated iC3b was assayed in the presence or absence of different concentrations of the integrin-activating compound IMB-10.<sup><xref ref-type="bibr" rid="bibr41-0961203313491851">41</xref></sup> Adhesion assays were conducted as in MacPherson et al.<sup><xref ref-type="bibr" rid="bibr28-0961203313491851">28</xref></sup> Briefly, iC3b (R&amp;D systems) was coated onto 96-well Maxisorp plates (Nunc) at a concentration of 2 µg/ml at 4°C. Wells were blocked with human serum albumin for two hours at 37°C, after which cells were added in binding medium (RPMI 1640, 0.1% BSA, 40 mM Hepes, 2 mM MgCl<sub>2</sub>), with increasing concentrations of IMB10 (Calbiochem) or with vehicle alone. Cells were allowed to adhere for 20 minutes at 37°C before unbound cells were removed by gentle washing with PBS/2 mM MgCl<sub>2</sub>. The bound cells were lysed in the presence of 3 mg/ml p-nitrophenyl phosphate (Calbiochem) and the plates developed with 1 M NaOH, after which the absorbance at 405 nm was measured. Interestingly, the IMB-10 compound partially rescues the adhesion defect caused by the R77H substitution in Mac-1. Statistically significant differences (<italic>p</italic> &lt; 0.05) in bracketed comparisons are indicated by an asterisk (Students <italic>t</italic> test).</p>
<p>SLE: systemic lupus erythematosus; RPMI: Roswell Park Memorial Institute; BSA: bovine serum albumin; PBS: phosphate-buffered saline.</p></caption><graphic xlink:href="10.1177_0961203313491851-fig2.tif"/>
</fig></p>
</sec>
<sec id="sec7-0961203313491851" sec-type="conclusions"><title>Conclusions</title>
<p>Studies of the <italic>ITGAM</italic> genetic variants which are linked to SLE have revealed that the R77H variant of the CD11b/Mac-1 receptor displays functional defects which may be relevant to SLE development. The R77H Mac-1 receptor is normally expressed on the surface of leucocytes, but is deficient in adhesion to integrin ligands. Importantly, the variant form is also deficient in mediating phagocytosis, and it is plausible that this is relevant to disease pathology as it relates to clearance of apoptotic cells. Furthermore, the R77H mutated receptor is deficient in restricting inflammatory cytokine production, which may also be relevant for SLE. Studies of SLE variants is an exciting area which could potentially shed light on the pathogenesis of SLE and lead to the discovery of novel drug targets.</p>
</sec>
</body>
<back><ack><title>Acknowledgement</title>
<p>We thank Professor Sara Marshall for valuable discussions and support.</p></ack>
<sec id="sec8-0961203313491851"><title>Funding</title>
<p>The work in the authors’ laboratories is funded by Arthritis Research UK, Biotechnology and Biological Sciences Research Council (BBSRC), Tenovus Scotland, the Anonymous Trust, Academy of Finland, Cancer Research UK, a J.C. Harkness Bequest and Research Grants Council, Hong Kong; and University Research Committee, The University of Hong Kong.</p>
</sec>
<sec id="sec9-0961203313491851"><title>Conflict of interest</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-0961203313491851"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>B</given-names></name><name><surname>Vyse</surname><given-names>TJ</given-names></name></person-group>. <article-title>The genetics of SLE: An update in the light of genome-wide association studies</article-title>. <source>Rheumatology (Oxford)</source> <year>2008</year>; <volume>47</volume>: <fpage>1603</fpage>–<lpage>1611</lpage>.</citation></ref>
<ref id="bibr2-0961203313491851"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hom</surname><given-names>G</given-names></name><name><surname>Graham</surname><given-names>RR</given-names></name><name><surname>Modrek</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Association of systemic lupus erythematosus with C8orf13-BLK and <italic>ITGAM-ITGAX</italic></article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>900</fpage>–<lpage>909</lpage>.</citation></ref>
<ref id="bibr3-0961203313491851"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>SK</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Kim-Howard</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>A nonsynonymous functional variant in integrin-alpha(M) (encoded by <italic>ITGAM</italic>) is associated with systemic lupus erythematosus</article-title>. <source>Nat Genet</source> <year>2008</year>; <volume>40</volume>: <fpage>152</fpage>–<lpage>154</lpage>.</citation></ref>
<ref id="bibr4-0961203313491851"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Alarcón-Riquelme</surname><given-names>ME</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci</article-title>. <source>Nat Genet</source> <year>2008</year>; <volume>40</volume>: <fpage>204</fpage>–<lpage>210</lpage>.</citation></ref>
<ref id="bibr5-0961203313491851"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>LH</given-names></name><name><surname>Pan</surname><given-names>HF</given-names></name><name><surname>Tao</surname><given-names>JH</given-names></name><name><surname>Sun</surname><given-names>ZQ</given-names></name><name><surname>Ye</surname><given-names>DQ</given-names></name></person-group>. <article-title>Association of ITGAM polymorphism with systemic lupus erythematosus: A meta-analysis</article-title>. <source>J Eur Acad Dermatol Venereol</source> <year>2011</year>; <volume>25</volume>: <fpage>271</fpage>–<lpage>275</lpage>.</citation></ref>
<ref id="bibr6-0961203313491851"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Kim-Howard</surname><given-names>X</given-names></name><name><surname>Deshmukh</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Evaluation of imputation-based association in and around the integrin-alpha-M (<italic>ITGAM</italic>) gene and replication of robust association between a non-synonymous functional variant within <italic>ITGAM</italic> and systemic lupus erythematosus (SLE)</article-title>. <source>Hum Mol Genet</source> <year>2009</year>; <volume>18</volume>: <fpage>1171</fpage>–<lpage>1180</lpage>.</citation></ref>
<ref id="bibr7-0961203313491851"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Hirankarn</surname><given-names>N</given-names></name><etal/></person-group>. <article-title><italic>ITGAM</italic> is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai</article-title>. <source>Hum Mol Genet</source> <year>2009</year>; <volume>18</volume>: <fpage>2063</fpage>–<lpage>2070</lpage>.</citation></ref>
<ref id="bibr8-0961203313491851"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim-Howard</surname><given-names>X</given-names></name><name><surname>Maiti</surname><given-names>AK</given-names></name><name><surname>Anaya</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title><italic>ITGAM</italic> coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry</article-title>. <source>Ann Rheum Dis</source> <year>2010</year>; <volume>69</volume>: <fpage>1329</fpage>–<lpage>1332</lpage>.</citation></ref>
<ref id="bibr9-0961203313491851"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellquist</surname><given-names>A</given-names></name><name><surname>Zucchelli</surname><given-names>M</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Identification of MAMDC1 as a candidate susceptibility gene for systemic lupus erythematosus (SLE)</article-title>. <source>PLoS One</source> <year>2009</year>; <volume>4</volume>: <fpage>e8037</fpage>–<lpage>e8037</lpage>.</citation></ref>
<ref id="bibr10-0961203313491851"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warchol</surname><given-names>T</given-names></name><name><surname>Lianeri</surname><given-names>M</given-names></name><name><surname>Lacki</surname><given-names>JK</given-names></name><name><surname>Olesinska</surname><given-names>M</given-names></name><name><surname>Jagodzinski</surname><given-names>PP</given-names></name></person-group>. <article-title><italic>ITGAM</italic> Arg77His is associated with disease susceptibility, arthritis, and renal symptoms in systemic lupus erythematosus patients from a sample of the Polish population</article-title>. <source>DNA Cell Biol</source> <year>2011</year>; <volume>30</volume>: <fpage>33</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr11-0961203313491851"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>EE</given-names></name><name><surname>Choi</surname><given-names>CB</given-names></name><etal/></person-group>. <article-title>Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries</article-title>. <source>Ann Rheum Dis</source> <year>2012</year>; <volume>71</volume>: <fpage>1809</fpage>–<lpage>1814</lpage>.</citation></ref>
<ref id="bibr12-0961203313491851"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anaya</surname><given-names>JM</given-names></name><name><surname>Kim-Howard</surname><given-names>X</given-names></name><name><surname>Prahalad</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Evaluation of genetic association between an <italic>ITGAM</italic> non-synonymous SNP (rs1143679) and multiple autoimmune diseases</article-title>. <source>Autoimmun Rev</source> <year>2012</year>; <volume>11</volume>: <fpage>276</fpage>–<lpage>280</lpage>.</citation></ref>
<ref id="bibr13-0961203313491851"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarvinen</surname><given-names>TM</given-names></name><name><surname>Hellquist</surname><given-names>A</given-names></name><name><surname>Koskenmies</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Polymorphisms of the <italic>ITGAM</italic> gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus</article-title>. <source>PLoS One</source> <year>2010</year>; <volume>5</volume>: <fpage>e14212</fpage>–<lpage>e14212</lpage>.</citation></ref>
<ref id="bibr14-0961203313491851"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suarez-Gestal</surname><given-names>M</given-names></name><name><surname>Calaza</surname><given-names>M</given-names></name><name><surname>Dieguez-Gonzalez</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors</article-title>. <source>Arthritis Rheum</source> <year>2009</year>; <volume>60</volume>: <fpage>2558</fpage>–<lpage>2564</lpage>.</citation></ref>
<ref id="bibr15-0961203313491851"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>SM</given-names></name></person-group>. <article-title>The leucocyte β2 (CD18) integrins: The structure, functional regulation and signalling properties</article-title>. <source>Biosci Rep</source> <year>2012</year>; <volume>32</volume>: <fpage>241</fpage>–<lpage>269</lpage>.</citation></ref>
<ref id="bibr16-0961203313491851"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Etzioni</surname><given-names>A</given-names></name></person-group>. <article-title>Genetic etiologies of leukocyte adhesion defects</article-title>. <source>Curr Opin Immunol</source> <year>2009</year>; <volume>21</volume>: <fpage>481</fpage>–<lpage>486</lpage>.</citation></ref>
<ref id="bibr17-0961203313491851"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gahmberg</surname><given-names>CG</given-names></name><name><surname>Fagerholm</surname><given-names>SC</given-names></name><name><surname>Nurmi</surname><given-names>SM</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Marchesan</surname><given-names>S</given-names></name><name><surname>Gronholm</surname><given-names>M</given-names></name></person-group>. <article-title>Regulation of integrin activity and signalling</article-title>. <source>Biochim Biophys Acta</source> <year>2009</year>; <volume>1790</volume>: <fpage>431</fpage>–<lpage>444</lpage>.</citation></ref>
<ref id="bibr18-0961203313491851"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>AE</given-names></name><name><surname>Larregina</surname><given-names>AT</given-names></name><name><surname>Shufesky</surname><given-names>WJ</given-names></name><etal/></person-group>. <article-title>Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: Dependence on complement receptors and effect on cytokine production</article-title>. <source>Blood</source> <year>2003</year>; <volume>101</volume>: <fpage>611</fpage>–<lpage>620</lpage>.</citation></ref>
<ref id="bibr19-0961203313491851"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillipson</surname><given-names>M</given-names></name><name><surname>Heit</surname><given-names>B</given-names></name><name><surname>Colarusso</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group>. <article-title>Intraluminal crawling of neutrophils to emigration sites: A molecularly distinct process from adhesion in the recruitment cascade</article-title>. <source>J Exp Med</source> <year>2006</year>; <volume>203</volume>: <fpage>2569</fpage>–<lpage>2575</lpage>.</citation></ref>
<ref id="bibr20-0961203313491851"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fagerholm</surname><given-names>SC</given-names></name><name><surname>Varis</surname><given-names>M</given-names></name><name><surname>Stefanidakis</surname><given-names>M</given-names></name><name><surname>Hilden</surname><given-names>TJ</given-names></name><name><surname>Gahmberg</surname><given-names>CG</given-names></name></person-group>. <article-title>alpha-Chain phosphorylation of the human leukocyte CD11b/CD18 (Mac-1) integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation</article-title>. <source>Blood</source> <year>2006</year>; <volume>108</volume>: <fpage>3379</fpage>–<lpage>3386</lpage>.</citation></ref>
<ref id="bibr21-0961203313491851"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Podgrabinska</surname><given-names>S</given-names></name><name><surname>Kamalu</surname><given-names>O</given-names></name><name><surname>Mayer</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism</article-title>. <source>J Immunol</source> <year>2009</year>; <volume>183</volume>: <fpage>1767</fpage>–<lpage>1779</lpage>.</citation></ref>
<ref id="bibr22-0961203313491851"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>G</given-names></name><name><surname>Balkow</surname><given-names>S</given-names></name><name><surname>Wild</surname><given-names>MK</given-names></name><etal/></person-group>. <article-title>Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation</article-title>. <source>Blood</source> <year>2007</year>; <volume>109</volume>: <fpage>661</fpage>–<lpage>669</lpage>.</citation></ref>
<ref id="bibr23-0961203313491851"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ehirchiou</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group>. <article-title>CD11b facilitates the development of peripheral tolerance by suppressing Th17 differentiation</article-title>. <source>J Exp Med</source> <year>2007</year>; <volume>204</volume>: <fpage>1519</fpage>–<lpage>1524</lpage>.</citation></ref>
<ref id="bibr24-0961203313491851"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group>. <article-title>Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b</article-title>. <source>Nat Immunol</source> <year>2010</year>; <volume>11</volume>: <fpage>734</fpage>–<lpage>742</lpage>.</citation></ref>
<ref id="bibr25-0961203313491851"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gordon</surname><given-names>RA</given-names></name><name><surname>Huynh</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins</article-title>. <source>Immunity</source> <year>2010</year>; <volume>32</volume>: <fpage>518</fpage>–<lpage>530</lpage>.</citation></ref>
<ref id="bibr26-0961203313491851"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kevil</surname><given-names>CG</given-names></name><name><surname>Hicks</surname><given-names>MJ</given-names></name><name><surname>He</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease</article-title>. <source>Am J Pathol</source> <year>2004</year>; <volume>165</volume>: <fpage>609</fpage>–<lpage>616</lpage>.</citation></ref>
<ref id="bibr27-0961203313491851"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yung</surname><given-names>R</given-names></name><name><surname>Powers</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice</article-title>. <source>J Clin Invest</source> <year>1996</year>; <volume>97</volume>: <fpage>2866</fpage>–<lpage>2871</lpage>.</citation></ref>
<ref id="bibr28-0961203313491851"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacPherson</surname><given-names>M</given-names></name><name><surname>Lek</surname><given-names>HS</given-names></name><name><surname>Prescott</surname><given-names>A</given-names></name><name><surname>Fagerholm</surname><given-names>SC</given-names></name></person-group>. <article-title>A systemic lupus erythematosus-associated R77H substitution in the CD11b chain of the Mac-1 integrin compromises leukocyte adhesion and phagocytosis</article-title>. <source>J Biol Chem</source> <year>2011</year>; <volume>286</volume>: <fpage>17303</fpage>–<lpage>17310</lpage>.</citation></ref>
<ref id="bibr29-0961203313491851"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>B</given-names></name><name><surname>Fürnrohr</surname><given-names>BG</given-names></name><name><surname>Roberts</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>The rs1143679 (R77H) lupus associated variant of <italic>ITGAM</italic> (CD11b) impairs complement receptor 3 mediated functions in human monocytes</article-title>. <source>Ann Rheum Dis</source> <year>2012</year>; <volume>71</volume>: <fpage>2028</fpage>–<lpage>2034</lpage>.</citation></ref>
<ref id="bibr30-0961203313491851"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fossati-Jimack</surname><given-names>L</given-names></name><name><surname>Ling</surname><given-names>GS</given-names></name><name><surname>Cortini</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells</article-title>. <source>PLoS One</source> <year>2013</year>; <volume>8</volume>: <fpage>e57082</fpage>–<lpage>e57082</lpage>.</citation></ref>
<ref id="bibr31-0961203313491851"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaipl</surname><given-names>US</given-names></name><name><surname>Voll</surname><given-names>RE</given-names></name><name><surname>Sheriff</surname><given-names>A</given-names></name><name><surname>Franz</surname><given-names>S</given-names></name><name><surname>Kalden</surname><given-names>JR</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name></person-group>. <article-title>Impaired clearance of dying cells in systemic lupus erythematosus</article-title>. <source>Autoimmun Rev</source> <year>2005</year>; <volume>4</volume>: <fpage>189</fpage>–<lpage>194</lpage>.</citation></ref>
<ref id="bibr32-0961203313491851"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Mok</surname><given-names>MY</given-names></name><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name></person-group>. <article-title>Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2003</year>; <volume>48</volume>: <fpage>2888</fpage>–<lpage>2897</lpage>.</citation></ref>
<ref id="bibr33-0961203313491851"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>VS</given-names></name><name><surname>Nie</surname><given-names>YJ</given-names></name><name><surname>Shen</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Mok</surname><given-names>MY</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name></person-group>. <article-title>Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus</article-title>. <source>Autoimmun Rev</source> <year>2012</year>; <volume>11</volume>: <fpage>890</fpage>–<lpage>897</lpage>.</citation></ref>
<ref id="bibr34-0961203313491851"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>EM</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Muvarak</surname><given-names>N</given-names></name><name><surname>Zoltick</surname><given-names>PW</given-names></name><name><surname>Flake</surname><given-names>AW</given-names></name><name><surname>Gallucci</surname><given-names>S</given-names></name></person-group>. <article-title>Apoptotic cell-mediated immunoregulation of dendritic cells does not require iC3b opsonization</article-title>. <source>J Immunol</source> <year>2008</year>; <volume>181</volume>: <fpage>3018</fpage>–<lpage>3026</lpage>.</citation></ref>
<ref id="bibr35-0961203313491851"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>MY</given-names></name><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Lo</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name></person-group>. <article-title>The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2010</year>; <volume>37</volume>: <fpage>2046</fpage>–<lpage>2052</lpage>.</citation></ref>
<ref id="bibr36-0961203313491851"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Spriel</surname><given-names>AB</given-names></name><name><surname>Leusen</surname><given-names>JH</given-names></name><name><surname>van Egmond</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation</article-title>. <source>Blood</source> <year>2001</year>; <volume>97</volume>: <fpage>2478</fpage>–<lpage>2486</lpage>.</citation></ref>
<ref id="bibr37-0961203313491851"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Spriel</surname><given-names>AB</given-names></name><name><surname>Leusen</surname><given-names>JH</given-names></name><name><surname>Vile</surname><given-names>H</given-names></name><name><surname>Van De Winkel</surname><given-names>JG</given-names></name></person-group>. <article-title>Mac-1 (CD11b/CD18) as accessory molecule for Fc alpha R (CD89) binding of IgA</article-title>. <source>J Immunol</source> <year>2002</year>; <volume>169</volume>: <fpage>3831</fpage>–<lpage>3836</lpage>.</citation></ref>
<ref id="bibr38-0961203313491851"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Spriel</surname><given-names>AB</given-names></name><name><surname>van Ojik</surname><given-names>HH</given-names></name><name><surname>Bakker</surname><given-names>A</given-names></name><name><surname>Jansen</surname><given-names>MJ</given-names></name><name><surname>van de Winkel</surname><given-names>JG</given-names></name></person-group>. <article-title>Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma</article-title>. <source>Blood</source> <year>2003</year>; <volume>101</volume>: <fpage>253</fpage>–<lpage>258</lpage>.</citation></ref>
<ref id="bibr39-0961203313491851"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>JM</given-names></name><name><surname>Edberg</surname><given-names>JC</given-names></name><name><surname>Kimberly</surname><given-names>RP</given-names></name></person-group>. <article-title>Pathways: Strategies for susceptibility genes in SLE</article-title>. <source>Autoimmun Rev</source> <year>2010</year>; <volume>9</volume>: <fpage>473</fpage>–<lpage>476</lpage>.</citation></ref>
<ref id="bibr40-0961203313491851"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosetti</surname><given-names>F</given-names></name><name><surname>Tsuboi</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Human lupus serum induces neutrophil-mediated organ damage in mice that is enabled by Mac-1 deficiency</article-title>. <source>J Immunol</source> <year>2012</year>; <volume>189</volume>: <fpage>3714</fpage>–<lpage>3723</lpage>.</citation></ref>
<ref id="bibr41-0961203313491851"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Björklund</surname><given-names>M</given-names></name><name><surname>Aitio</surname><given-names>O</given-names></name><name><surname>Stefanidakis</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Stabilization of the activated alphaMbeta2 integrin by a small molecule inhibits leukocyte migration and recruitment</article-title>. <source>Biochemistry</source> <year>2006</year>; <volume>45</volume>: <fpage>2862</fpage>–<lpage>2871</lpage>.</citation></ref>
<ref id="bibr42-0961203313491851"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maiguel</surname><given-names>D</given-names></name><name><surname>Faridi</surname><given-names>MH</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease</article-title>. <source>Sci Signal</source> <year>2011</year>; <volume>4</volume>: <fpage>ra57</fpage>–<lpage>ra57</lpage>.</citation></ref>
<ref id="bibr43-0961203313491851"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>JH</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: Implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins</article-title>. <source>J Biol Chem</source> <year>2013</year>; <volume>288</volume>: <fpage>9077</fpage>–<lpage>9083</lpage>.</citation></ref>
</ref-list>
</back>
</article>